SVB Wealth’s Ironwood Pharmaceuticals IRWD Stock Holding History

SVB Wealth’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-121	Closed	-$178	–	1050
2025 Q1	$178	Buy	+121	New	+$288	﹤0.01%	1478

Other funds holding IRWD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SVB Wealth's IRWD Position: Q2 2025 in Review

SVB Wealth sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2025, closing a stake of 121 shares — an estimated $178 sold.

SVB Wealth first reported a position in IRWD in Q1 2025 and held it in 1 quarter. The position peaked at $178 in Q1 2025. 155 funds tracked by Wall St. Rank hold IRWD as of Q2 2025.

SVB Wealth reported no remaining Ironwood Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 121 Ironwood Pharmaceuticals shares in Q2 2025, an estimated $178.
SVB Wealth first reported a position in Ironwood Pharmaceuticals in Q1 2025 and held it in 1 quarter.
SVB Wealth's Ironwood Pharmaceuticals position peaked at $178 in Q1 2025.
155 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.